Preimplantation genetic testing for monogenic disorders (PGT-M) and preimplantation genetic testing for human leukocyte antigen (PGT-HLA) are both advanced genetic testing methods used during in vitro fertilization (IVF). PGT-M screens embryos for single-gene disorders, such as cystic fibrosis or sickle cell anemia, ensuring that only embryos without the genetic condition are selected for implantation. PGT-HLA, on the other hand, tests embryos to identify those that are compatible as potential tissue donors for a sibling with a specific genetic condition requiring a stem cell or bone marrow transplant. PGT-HLA is typically used in cases where a family has a child with a life-threatening condition that could benefit from stem cell therapy. Both tests involve embryo biopsy, genetic analysis, and the selection of healthy embryos for implantation. These technologies enhance reproductive success and offer a way to prevent serious genetic disorders. Together, PGT-M and PGT-HLA provide personalized reproductive options for couples facing genetic challenges.